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Abstract 
This study aimed at investigating plant species that are used locally in Zimbabwe to manage 
diabetes type 2 and their respective modes of action using in vitro studies. The plants for this study 
were identified by ethnobotanical studies and their respective antidiabetic potentials were 
evaluated using protein tyrosine phosphatase 1B (PTP 1B) and dipeptidyl peptidase IV (DPP IV) 
inhibition assays. Out of the 15 plant species used to manage diabetes in traditional practices, 9 
inhibited PTP 1B with half maximal inhibitory concentrations (IC50) ranging from 0.03 ± 0.00 to 
61.31 ± 0.70 µg/mL. The mechanism of inhibition deduced from Lineweaver-Burk plot was non-
competitive inhibition for Bridelia micrantha, Brachylaena discolor, Artemisia afra, Sutherlandia 
frutescens and Euclea undulate, while Ziziphus mucronta extract inhibited PTP 1B enzyme in a 
competitive pattern. The inhibition mechanism was demonstrated by decreasing or constant Km 
and Vmax values.  Km values ranged from 1.00 to 3.33 mM. Also 9 plant species out of the 15 
studied showed DPP IV inhibition activity. Four plant species, Sutherlandia frutescens, 
Momordica balsamina, Bulbine latifola, and Spirostachys africanus exhibited inhibitory activity 
that was comparable to the approved DPP IV tight binding drug, sitagliptin with percentage 
inhibition ≥ 73.55 ± 0.32%. The present results provide a scientific base for the current uses of the 
plant species in local management of diabetes type 2. Thus these plants are not only useful in 
polyherbal formulations for management of diabetes type 2, but also serve as sources of lead 
compounds for further studies toward developing drugs for treating diabetes type 2. 
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Introduction 
Diabetes type 2 is an adult onset 
metabolic disorder that arises following 
deficiency of insulin or cells insensitivity to 
insulin (Shah et al. 2016). The worldwide 
trends of increasing cases of diabetes type 2 
have created threats to human health globally 
(WHO 2018).  The disease causes several 
secondary complications, particularly, 
atherosclerosis, renal dysfunction and failure 
and diabetic retinopathy (Wang et al. 2015). 
Currently, diabetes type 2 is treated by eight 
types of oral hypoglycaemic drug types; α-
glucosidase inhibitors, glucagon-like peptide-
1 receptor agonist, amylin analogs, insulin 
secretagogues, thiazolidinediones, biguanides, 
dipeptidyl peptidase-4 inhibitors and sodium-
glucose cotransporter-2 inhibitors (Bӧsenberg 
and Van Zyl, 2008, Riyanti et al. 2016). 
Nevertheless, the complications associated 




with their administration to patients, 
markedly; gastrointestinal complaints, weight 
gain, peripheral oedema, headache and 
hypertension, these drugs are effective 
hypoglycaemic agents and have been widely 
used to treat diabetes type 2. Those 
limitations are because mechanistically they 
are not targeting insulin mediated cell 
signaling mechanism (Moller 2001). Thus, 
drugs that target the negative regulation of 
insulin signaling are urgently needed. 
Recently, polyherbal formulations have 
gained attention because they are affordable 
and have demonstrated less side effects. 
Protein tyrosine phosphatase constitutes 
enzymes that catalyze tyrosine 
dephosphorylation-dependent cellular 
functions, including the PTP 1B which 
catalyzes the negative regulation of insulin 
signaling mechanism (Quang et al. 2015). 
Several studies have shown that the cytosolic 
non-receptor protein tyrosine phosphatase 1B 
(PTP 1B) obstruct insulin signal transduction 
(Zhang and Lee 2003, Koren and Fantus 
2007). Thus PTP 1B has proved to be a 
crucial drug target for management of 
diabetes type 2. Many inhibitors of PTP 1B 
such as vanadium compounds, sulphonic 
acids, phosphonic acids, carboxylic acids and 
imides have been synthesized. These are non-
hydrolysable p-tyrosine surrogates that bind 
on either the catalytic site or the allosteric 
pocket or both (Combs 2010, Jiang et al. 
2012). However, these compounds lack in 
vivo potency due to both poor oral 
bioavailability and permeability to 
membranes. The compounds have also failed 
to discriminate PTP 1B among the several 
protein tyrosine phosphatases (Cragg et al. 
2009). Thus, the searches for novel 
compounds that selectively inhibit protein 
tyrosine phosphatase 1B are still on going.  
DPP IV is a serine protease which 
degrades proline or alanine containing 
peptides (Havale and Pal 2009). The enzyme 
degrades incretins, specifically glucagon-like 
peptide 1 and glucose-dependent 
insulinotropic polypeptide hormones which 
are released into the intestine in response to 
nutrient intake and stimulate insulin secretion 
(Brubaker and Drucker 2004, Calero et al. 
2014). Therefore, incretins peptides which 
maintain insulin homeostasis are short lived 
due to their rapid degradations by DPP IV 
which result into diabetes type 2. Thus, the 
inhibition of DPP IV enzymes increases the 
shelf-lives of glucagon-like peptide 1 and 
glucose-dependent insulinotropic polypeptide 
which maintains the secretion of insulin with 
overall effects on deterrence of increasing 
level of glucose in the blood. 
Plants are well known for varieties of 
compounds with diverse bioactivities, thus 
offer more opportunities for searching novel 
drugs and lead compounds (Jiang et al. 2012). 
Based on this, researchers are now concerned 
with screening plants for potential PTP 1B 
and DPP IV inhibitors that can reduce insulin 
resistance and normalize plasma glucose 
without inducing hypoglycaemia. In line with 
this thrust, this study was designed to 
investigate local plants purported to have 
antidiabetic activities in traditional practices 
and screen for PTP 1B and dipeptidyl 
peptidase IV (DPP IV) inhibition with an 
overall aim of providing impetus in the use of 
the plants to formulate polyherbal drugs to 
fight diabetes type 2. 
 
Materials and Methods 
Materials 
All solvents and buffers were of analytical 
grade. Except for buffers that were sourced 
from local chemical suppliers, the rest of the 
chemicals and reagents (solvents, enzymes 
and standards) were purchased from Sigma 
Aldrich, Germany. A UV-Vis 
spectrophotometer, GENESYS 10S UV-Vis 
v4.003 2L9Q129001 ThermoFisher 
Scientific, USA) was used to monitor the 
progress of reactions. 
 
Ethnobotanical surveys and collection of 
plant materials 
Plant materials were collected from 
Mashonaland Central and East Forests with 
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the help of traditional practitioners certified 
by Zimbabwe National Traditional Healers 
Association (ZINATHA) and local elderly 
people. Ten traditional practitioners from 
each village were orally interviewed. The 
study area consisted of a total of 8 villages. 
Plants yielding a quote frequency > 60% of 
the respondents were collected. A further 
literature survey was conducted by searching 
scientific studies and websites reporting 
similar uses as those reported by the 
traditional healers using various search 
engines such as Google scholar, Google, 
Pubmed, and SciFinder. The key searching 
words included medicinal uses, diabetes uses 
and ethnobotanical use. A total of 15 plant 
species were identified as anti-diabetes herbs 
by the traditional healers and were collected. 
The full plant list and medicinal uses are 
shown in Table 1. Plant species authentication 
was done by the help of the Harare National 
Herbarium and information from literature. 
Voucher specimens were deposited in the 
Bindura University of Science Education 
natural product section for future references.  
 
Ethical approval 
All procedures performed in studies involving 
humans were in accordance with the ethical 
standards of the Bindura University Ethics 




Five fractions of organic extracts from dried 
powdered materials of each plant were 
obtained after sequential extraction by 
organic solvents with increasing polarity 
(100% n-hexane, 100% ethyl-acetate, 75: 25 
% ethyl-acetate/ethanol mixture, 50: 50% 
ethyl-acetate/ethanol mixture and 100% 
ethanol). In each extraction, the sample 
material (10 g) was shaken with solvent (50 
mL) for 2 hours before filtered and finally 




PTP1B inhibition assay 
PTP 1B inhibition assay was carried out 
according to a slightly modified literature 
reported method by Shah et al. (2016). The 
analyses were carried out in the reaction 
mixtures composed of extracts in the 
concentration range of 0-100 µg/mL, p-
nitrophenol phosphate (2 mM) in bis-tris 
buffer (50 mM,  pH 7.2) and PTP 1B (10 
mM). The mixtures were incubated at 37 °C 
for 30 minutes followed by termination by 
adding 20 µL of 10 M NaOH. The amount of 
p-nitrophenol produced was determined by 
measuring the increase in absorbance at 405 
nm using a UV-Vis spectrophotometer, p-
nitrophenol which were formed non-
enzymatically were also determined 
spectrophotometrically at 405 nm without 
PTP 1B. Similar experiments were repeated 
with ursolic acid as a reference standard. The 
assays were carried out in triplicate, and 
results were used to compute IC50 values.  
 
Enzyme kinetic studies 
Crude extracts which exhibited inhibitions 
significantly greater than ursolic acid were 
selected for kinetic studies in order to 
determine the type of inhibition. The 
experimental conditions were as described 
before in PTP 1B inhibition assy. The assays 
for the kinetic studies were carried out in 
different concentrations of extracts, 0-6 
µg/mL and p-nitrophenol phosphate, 0-1.5 
mM. The rate of increase of absorbance at 





 for 0.5 M EDTA (Chen et al. 
2010) was used to compute initial rates. 
Lineweaver-Burk plot analyses were then 
used to estimate the magnitude of (Km) and 
maximum velocity (Vmax), Table 3. 
 
Dipeptidyl IV (DPPIV) inhibition assay 
DPPIV inhibition effectiveness by plants 
extracts were screened by using a method 
reported by Bharti et al. (2012) with minor 
modifications. Using a 96 well plate set up, 
the chromogenic substrate Gly-pro-p-
nitroanilidine (GPPN) is broken down by the 




serine protease DPPIV enzyme to 
paranitroanilidine (pNA), a yellow coloured 
compound that was monitored at 405 nm. 
Crude extracts or sitagliptin (standard 
inhibitor of DPPIV) were diluted to various 
concentrations 0.2, 0.4, 0.8, 1.6, 3.2 and 6.4 
µg/mL using tris HCl buffer (50 mM, pH 7.5) 
to a final volume of 35 µL. Absorbance of the 
solutions were recorded at 405 nm followed 
by adding of  DPPIV (0.05 U/mL, 15 µL). 
One unit of enzyme was taken as the amount 
of an enzyme required to catalyze the 
production of 1 µM of pNA per minute. The 
mixture was pre-incubated for 10 minutes at 
37 °C to allow maximum contact of enzyme 
with inhibitor followed by addition of GPPN 
(0.2 mM, 50 µL) in tris HCl (50 mM, pH 
7.5). The resultant mixture was incubated at 
37 °C for 30 minutes. The reaction was 
terminated by adding glacial acetic acid 
(25%, 25 µL). The absorbance results were 
compared with results of a control experiment 
(without inhibitor). The percentage inhibition 








where %I = percentage inhibition, AC = 
absorbance of control experiment (without 
inhibitor) and AS = absorbance of experiment 
with standard inhibitor or with extracts. 
 
Statistical analysis  
The results are expressed as mean plus or 
minus standard deviation (  ̅ ± SD) of three 
replicate analyses. Differences between the 
group means were analyzed using the IBM 
SPSS version 20 software by applying one 
way ANOVA with the Turkey-Karner post 
hoc test to identify significance of the 
differences among groups. A p value < 0.05 
was considered to be statistically significant. 
 
Results 
PTP1B inhibition assay 
A total of 15 plants (Table 1) were reported to 
be antidiabetic in traditional practices, and 
among these, only Spirostachys africanus and 
Keostis nana showed no PTP 1B inhibitory 
activity as shown in Table 2. Extracts from 
Bridelia micrantha, Euclea undulate, Euclea 
crispa, Ziziphus mucronta, Brachylaena 
discolor, Artemisia afra, Sutherlandia 
frutescens, and Bulbine latifola showed 
significantly greater (p < 0.05) PTP 1B 
inhibitory activities, with IC50 values < 0.2 
µg/mL than the standard inhibitor (ursolic 
acid) that had an IC50 value of 3.20 ± 0.20 
µg/mL. Bridelia micrantha, Euclea undulate, 
Euclea crispa, Ziziphus mucronta, 
Brachylaena discolor, Artemisia afra and 
Sutherlandia frutescens showed the greatest 
PTP 1B inhibitory activities with IC50 values 
≤ 0.05 µg/mL. Samples extracted using 100% 
ethyl acetate and ethyl acetate/ethanol 
mixture (75:25 v/v) showed the greatest PTP 
1B inhibitory activities (p < 0.05). With 1:1 
ethyl acetate/ethanol extracts, only those of 
Artemisia afra and Sutherlandia frutescens 
showed greater PTP 1B inhibitory activity 
with IC50 values of 0.03 ± 0.00 and 0.08 ± 
0.00 µg/mL, respectively.  
 
Table 1: Summary of the results obtained from ethnobotanical survey and literature search 
Plant name 
 
Uses with quote frequency  





Bridelia micrantha Fruit tree, against stomach ache, antidiabetic  7 2 
Euclea undulata Antidiabetic, 3 1 
Euclea crispa Anti-HIV, anti-inflammatory, antidiabetic 5 4 
Spirostachys africanus Against ulcers, antidiabetic, anti-malaria, 
against cough and headache 
4 1 
Ziziphus mucronta Antidiabetic, pain killer, against wound 
infections 
6 3 
Terminalia sericea Wound infections, diabetes,  4 3 
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Brachylaena discolor Diabetes, kidney problems, chest pains 7 5 
Bulbine latifola Diabetes, rheumatism, burns, rashes, 
itchiness 
8 4 
Lannea edulis Diabetes, diarrhoea 5 5 
Pteronia divaricate Diabetes, hypertension 6 2 
Warburgia salutaris Malaria remedy, diabetes, cough 7 2 
Momordica  balsamina Diabetes, analgesic 6 2 
Keostis nana Diabetes 6 2 
Artemisia afra Diabetes 7 4 
Sutherlandia frutescens Diabetes 4 3 
 
Table 2: PTP 1B inhibitory activity by organic extracts of different plant species and the standard 
inhibitor, ursolic acid. 1 = 100% n-hexane, 2 = 100% ethyl-acetate, 3 = 75: 25 % ethyl-
acetate/ethanol mixture, 4 = 50: 50% ethyl-acetate/ethanol mixture and 5 = 100% ethanol). NI = 
no inhibition 
Plant species Plant material Extract PTP 1B inhibitory activity (IC50 
values, µg/mL) 
Bridelia micrantha Bark 1 33.70 ± 0.00 
2 0.20 ± 0.02 
3 0.05 ± 0.02 
4 1.20 ± 0.60 
5 31.10 ± 0.50 
Euclea undulate Roots 1 9.20 ± 0.06 
2 0.06 ± 0.02 
3 2.25 ± 0.09 
4 3.00 ± 0.00 
5 31.50 ± 0.50 
Euclea crispa Leaves 1 7.33 ± 0.10 
2 0.13 ± 0.07 
3 0.12 ± 0.05 
4 61.31 ± 0.70 
5 33.18 ± 0.80 





Ziziphus mucronta Leaves 1 9.06 ± 0.11 
2 5.20 ± 0.12 
3 0.05 ± 0.02 
4 1.21 ± 0.20 
5 5.10 ± 0.10 
Terminalia sericea Bark 1 6.06 ± 0.13 
2 6.20 ± 0.02 
3 7.85 ± 0.02 
4 8.31 ± 0.20 
5 5.12 ± 0.30 
Brachylaena discolor Leaves 1 5.02 ± 0.00 
2 0.20 ± 0.02 
3 0.05 ± 0.00 
4 1.01 ± 0.00 
5 6.20 ± 0.10 




Table 2 (Ctd) 
Bulbine latifola Leaves 1 8.15 ± 0.01 
2 0.12 ± 0.02 
3 0.10 ± 0.01 
4 1.01 ± 0.00 
5 10.00 ± 0.01 
Lannea edulis Roots 1 10.13 ± 0.11 
2 13.22 ± 0.12 
3 9.15 ± 0.08 
4 11.21 ± 0.21 
5 9.27 ± 0.20 
Pteronia divaricate Bark 1 10.26 ± 0.30 
2 8.55 ± 0.12 
3 9.09 ± 0.08 
4 12.21 ± 0.24 
5 12.20 ± 0.22 
Warburgia salutaris Bark 1 7.62 ± 0.30 
2 13.23 ± 0.12 
3 6.15 ± 0.10 
4 11.21 ± 0.10 
5 9.10 ± 0.09 
Momordica  balsamina Fruits 1 9.12 ± 0.10 
2 8.30 ± 0.22 
3 10.32 ± 0.15 
4 5.21 ± 0.10 
5 9.23 ± 0.07 





Artemisia afra Leaves 1 3.08 ± 0.00 
2 0.03 ± 0.00 
3 0.05 ± 0.00 
4 0.03 ± 0.00 
5 4.50 ± 0.10 
Sutherlandia frutescens Bark 1 5.02 ± 0.02 
2 5.20 ± 0.02 
3 0.05 ± 0.00 
4 0.08 ± 0.00 
5 3.20 ± 0.10 
Leaves 1 NI 
2 10.40 ± 0.02 
3 8.51 ± 0.06 
4 7.11 ± 0.02 
5 9.33 ± 0.11 
Ursolic acid - 5 3.20 ± 0.20 
 
Enzyme kinetic studies 
In order to determine the kinetics of PTP 1B 
inhibitions by the extracts, each extract was 
assayed in different constant concentrations 
while the concentrations of pNPP were varied 
(Figure 1). The kinetic constants (Km) and 
maximum velocity (Vmax) were estimated 
from the intercept of the vertical and 
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horizontal axis of the double reciprocal plots, 
Figure 1 (i) and (iii-vi) which demonstrated 
the reduction in Vmax values without changes 
in Km. (Table 3). These results are translated 
to non-competitive inhibition patterns. Figure 
1 (ii) and Table 3 demonstrate change of Km 
while Vmax remained constant as the 
concentrations of the extract were increased. 
This showed that Ziziphus mucronta extract 
inhibited PTP 1B enzyme inhibition in a 
competitive pattern. 
 
Dipeptidyl IV (DPPIV) inhibition assay 
Nine of the plant species reported to be 
remedies for diabetes in 
ethnopharmacological study showed 
dipeptidyl IV (DPPIV) inhibition activities 
(Table 4). Sutherlandia frutescens, 
Momordica balsamina, Bulbine latifola, and 
Spirostachys africanus showed inhibitory 
activities that were comparable to that of the 
standard inhibitor (sitagliptin), ≥ 73.55 ± 
0.32%. Sitagliptin is a fast, tight binding and 
reversible DPP IV inhibitor. Of all the plants 
evaluated using DPPIV inhibition assays, 






Figure 1: Lineweaver-Burk plots for the inhibition of PTP 1B hydrolysis of p-NPP by ethyl 
acetate/ethanol (75:25) extracts of (i) Bridelia micrantha, (ii) Ziziphus mucronta, (iii) Brachylaena 








































































































































Table 3: Km and Vmax values for the extracts with significant PTP IB inhibition percentages 
 Extract Km (mM) Vmax(mMmin
–1) 
Without inhibitor Ethyl acetate/ethanol (75:25) 2.00 2.00 
With Bridelia micrantha extract Ethyl acetate/ethanol (75:25) 2.00 1.00 
Without inhibitor Ethyl acetate/ethanol (75:25) 3.33 3.30 
With Ziziphus mucronta extract  Ethyl acetate/ethanol (75:25) 2.50 3.30 
Without inhibitor Ethyl acetate/ethanol (75:25) 1.00 2.50 
With Brachylaena discolor extract  Ethyl acetate/ethanol (75:25) 1.00 0.43 
Without inhibitor Ethyl acetate/ethanol (75:25) 1.11 1.43 
With Artemisia afra extract Ethyl acetate/ethanol (75:25) 1.11 0.40 
Without inhibitor Ethyl acetate/ethanol (75:25) 1.67 3.33 
With Sutherlandia frutescens extract Ethyl acetate/ethanol (75:25) 1.67 0.50 
Without inhibitor Ethyl acetate (100%) 2 4 
With Euclea undulate extract Ethyl acetate (100%) 2 0.50 
 
Table 4: Percentage dipeptidyl IV (DPPIV) inhibition activities of different plant species and the 
standard inhibitor, sitagliptin. 1 = 100% n-hexane, 2 = 100% ethyl-acetate, 3 = 75: 25 % ethyl-
acetate/ethanol mixture, 4 = 50: 50% ethyl-acetate/ethanol mixture and 5 = 100% ethanol). NI = 
no inhibition 
Plant species Plant material Extract DPPIV inhibitory activity (%) 





Euclea undulate Roots 1 NI 
2 22.12 ± 0.31 
3 33.02 ± 1.22 
4 21.00 ± 0.21 
5 52.27 ± 0.09 
Euclea crispa Leaves 1 55.13 ± 1.24 
2 35.17 ± 0.55 
3 33.11 ± 1.52 
4 50.00 ± 0.21 
5 52.04 ± 2.01 
Spirostachys africanus Bark 1 75.52 ± 2.00 
2 77.44 ± 1.61 
3 79.81 ± 2.02 
4 70.00 ± 0.92 
5 78.14 ± 1.01 
Ziziphus mucronta Leaves 1 65.87 ± 1.33 
2 72.04 ± 0.92 
3 33.18 ± 1.00 
4 59.00 ± 0.10 
5 52.84 ± 2.00 
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Table 4 (Ctd)  





Bulbine latifola Leaves 1 81.10 ± 1.14 
2 76.00 ± 0.55 
3 83.21 ± 2.02 
4 80.00 ± 2.21 
5 52.04 ± 3.10 










Warburgia salutaris Bark 1 5.12 ± 1.02 
2 5.18 ± 2.05 
3 3.18 ± 0.90 
4 5.00 ± 0.51 
5 2.01 ± 0.01 
Momordica  balsamina Fruits 1 75.86 ± 1.83 
2 78.32 ± 1.51 
3 73.41 ± 1.22 
4 70.00 ± 2.23 
5 82.04 ± 2.40 





Artemisia afra Leaves 1 35.10 ± 1.33 
2 22.07 ± 1.63 
3 13.18 ± 1.22 
4 30.10 ± 1.33 
5 22.06 ± 1.01 
Sutherlandia frutescens Bark 1 75.18 ± 1.00 
2 85.13 ± 1.55 
3 73.13 ± 1.22 
4 76.55 ± 2.11 
5 72.44 ± 1.50 
Leaves 1 85.16 ± 1.89 
2 75.12 ± 1.65 
3 73.19 ± 1.92 
4 77.30 ± 2.20 
5 72.14 ± 1.93 
Sitagliptin  - Water 73.55 ± 0.32 
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Discussion 
Despite the ethnobotanical survey 
description of folklore medicine anti-diabetic 
uses of the 15 plants reported in the present 
studies (Ribeiro et al. 2010, Deutschländer et 
al. 2009), scientific information to justify 
their traditional uses has remained limited. 
PTP 1B has long been used as a validated 
drug target for the search of anti-diabetic 
drugs. The in vitro studies showed that a 
number of the plants showed PTP 1B 
inhibitory activities that were significantly 
greater than that by a pentacyclic triterpenoid 
acid (ursolic acid) that is widely used as 
standard natural inhibitor (Zhang et al. 2006). 
The IC50 values of the bioactive plants ranged 
from 0.03 ± 0.00 to 61.31 ± 0.70 µg/mL, 
while that for ursolic acid is 3.20 ± 0.20 
µg/mL.  
Crude extracts obtained using ethyl-
acetate (100%), ethyl-acetate/ethanol (75: 25 
% v/v), ethyl-acetate/ethanol (50: 50% v/v) 
showed the greatest inhibitory activities than 
hexane (100%) and ethanol (100%). This 
shows that the bioactive compounds are 
moderately polar. These results are interesting 
since the current thrust in PTP 1B inhibitors 
search is to find orally available lipophilic 
compounds that do not pose a challenge in 
passing through the highly lipophilic cell 
membranes (Johnson et al. 2002). All the 
known clinical PTP 1B inhibitors contain 
functional groups that mimic a phosphate, 
therefore are negatively charged. Such 
charged compounds have reduced abilities to 
permeate cell membranes and are not 
favourable for intestinal transcellular 
absorption (Palm et al. 1997). Bridelia 
micrantha, Ziziphus mucronta, Brachylaena 
discolor, Artemisia afra and Sutherlandia 
frutescens crude extracts IC50 values less than 
3.20 ± 0.20 µg/mL, exhibited inhibitory 
activities that were approximately 100 fold 
greater than that for ursolic acid. The IC50 
values were ≤ to 0.05 µg/mL.  
Lineweaver-Burk plots were used to 
establish the mechanisms of inhibition for 
Bridelia micrantha, Ziziphus mucronta, 
Brachylaena discolor, Artemisia afra and 
Sutherlandia frutescens crude extracts. The 
results in Figure 1 and Table 3 show that the 
crude extracts exhibit a non-competitive PTP 
1B inhibitory pattern. This implies that the 
bioactive compounds target the allosteric sites 
of the enzyme. Previous studies postulated the 
potency of noncompetitive PTP 1B inhibitors 
that target the enzyme allosteric site and 
prospects of developing efficacious anti-
diabetic drugs from such inhibitors (Liu et al. 
2008). Therefore, the present study has also 
identified the plants as sources of lead 
compounds for developing drugs to treat 
diabetes type 2. 
Nine out of the 15 plants reported in the 
present study showed dipeptidyl IV (DPP IV) 
inhibition activities. DPP IV is involved in the 
degradation of glucagon like peptide-1, a 
potent insulinotropic peptide (Gallwitz 2008). 
Besides supporting the current uses of plants 
locally, these results also illustrate the 
significance of inhibiting DPP-IV as an 
effective approach to treat type 2 diabetes 
mellitus by promoting insulin secretion. 
Bridelia micrantha, Terminalia sericea, 
Brachylaena discolor, Lannea edulis and 
Pteronia divaricate showed PTP 1B 
inhibitory activities. However, the plants 
could not inhibit DPP IV. Out of the nine 
plants which showed PTP IB inhibitory 
activities, only 4 plants, that is, Sutherlandia 
frutescens, Momordica balsamina, Bulbine 
latifola, and Spirostachys africanus portrayed 
activities that were significantly comparable 
to that of the commercial drug sitagliptin. 
Since the current anti DPP IV active drugs; 
vildagliptin, sitagliptin and sexagliptin have a 
number of considerable side effects like 
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tremors, dizziness, nausea, weakness, weight 
gain and leg edema due to excessive fluid 
retention to some patients, Sutherlandia 
frutescens, Momordica balsamina, Bulbine 
latifola, and Spirostachys africanus can 
function as alternative drugs or as sources of 
lead compounds for the development of new 
diabetes mellitus type 2 drugs. The herbal 
drugs may be useful in treatment or 
management of impaired glucose tolerance, 
insulin resistance and hyperinsulinemia. 
Plants which did not show either PTP IB or 
DPP IV inhibition might be acting by 




The present study shows the importance of 
folklore medicine in management of diabetes 
type 2. Out of the 15 plants encountered in the 
present study, 9 are active against PTP IB. 
Also 9 plants inhibited DPP IV.  Only 4 
plants had both PTP IB and DPP IV 
inhibitory activities. The PTP IB inhibition 
activity depends on the solvent used in 
extraction. Ethyl acetate extracts showed the 
greatest activity which implied the anti-
diabetic active components of the extracts are 
moderate polar.  
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